药物转运体和代谢酶联合突变对那格列奈药效学的影响(2)
第1页 |
参见附件。
参考文献
[1]詹伟彬,黄公才.那格列奈治疗新诊断2型糖尿病临床效果观察. 实用医学杂志,2007,23(8):1240-41
[2]Kirchheiner J, Roots I, Goldammer M, et al. Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 3A4 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs. Clin Pharmacokinet, 2005, 44 (12):1209-1225.
[3]Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther, 2008, 77(6):468-478.
[4]Ortiz MG, Salazar EH, Abundis EM, Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals. Journal of Diabetes and Its Complications, 2005, 19:356– 360.
[5]Zhang W, He YJ, HanCT, et al, Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol, 2008, 62(5): 567–572.
[6]Kirchheiner J, Meineke I, Muller G, et al. Influence of CYP3A4 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers. Clin Pharmacokinet 2007, 43 (4): 267-278.
您现在查看是摘要介绍页,详见PDF附件。